树突细胞内在的PTPN22负面调节抗瘤免疫力,并影响抗PD-L1疗效
Santiago Acero-Bedoya1, Emily F Higgs2, Anna C Martinez1
1Pathology, University of Chicago Biological Sciences Division, Chicago, Illinois, USA.
Journal for immunotherapy of cancer
|October 26, 2024
概括
在树突细胞中去除PTPN22通过增强T细胞反应和瘤控制来增强抗瘤免疫力. 这表明PTPN22是癌症免疫治疗的潜在治疗标.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 分子生物学分子生物学
背景情况:
- 一种PTPN22基因变异增加了自身免疫性疾病的风险,并可能改善癌症患者的免疫治疗反应.
- 在癌症模型中,PTPN22作为T细胞反应的负调节剂.
- 在以前,PTPN22在树突细胞 (DCs) 中的特定作用未被定义.
研究的目的:
- 调查PTPN22在树突细胞 (DCs) 中的作用,在抗瘤免疫的背景下.
- 确定DC中PTPN22的删除是否增强了对癌症的免疫反应.
- 探索PTPN22作为癌症免疫治疗的潜在治疗标.
主要方法:
- 开发了一种新的PTPN22条件淘汰 (cKO) 鼠标模型,在CD11c+DCs中具有特定的删除.
- 使用B16.SIY和MC38.SIY癌症模型评估抗瘤免疫力.
- 通过光谱流细胞计分析了免疫细胞概况,并特征了DC功能ex vivo.
主要成果:
- 在DC中删除PTPN22增强了抗瘤免疫力,并在同源模型中改善了瘤控制.
- 在瘤微环境中观察到CD8+ T细胞反应的增加,并且依赖于CD8+ T细胞.
- 发现了增强的DC扩散,抗原处理和呈现,与抗PD-L1疗法相结合的益处.
结论:
- 在DC中删除PTPN22增强了瘤抗原特异性T细胞反应和瘤控制.
- PTPN22对DC扩散和抗原处理/呈现产生负面调节.
- 在DC中准PTPN22代表了癌症免疫治疗的有希望的策略.
相关概念视频
Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K


